Literature DB >> 19645002

Tungsten-induced protein aggregation: solution behavior.

Yijia Jiang1, Yasser Nashed-Samuel, Cynthia Li, Wei Liu, Joey Pollastrini, David Mallard, Zai-Qing Wen, Kiyoshi Fujimori, Monica Pallitto, Lisa Donahue, Grace Chu, Gianni Torraca, Aylin Vance, Tony Mire-Sluis, Erwin Freund, Janice Davis, Linda Narhi.   

Abstract

Tungsten has been associated with protein aggregation in prefilled syringes (PFSs). This study probed the relationship between PFSs, tungsten, visible particles, and protein aggregates. Experiments were carried out spiking solutions of two different model proteins with tungsten species obtained from the extraction of tungsten pins typically used in syringe manufacturing processes. These results were compared to those obtained with various soluble tungsten species from commercial sources. Although visible protein particles and aggregates were induced by tungsten from both sources, the extract from tungsten pins was more effective at inducing the formation of the soluble protein aggregates than the tungsten from other sources. Furthermore, our studies showed that the effect of tungsten on protein aggregation is dependent on the pH of the buffer used, the tungsten species, and the tungsten concentration present. The lower pH and increased tungsten concentration induced more protein aggregation. The protein molecules in the tungsten-induced aggregates had mostly nativelike structure, and aggregation was at least partly reversible. The aggregation was dependent on tungsten and protein concentration, and the ratio of these two and appears to arise through electrostatic interaction between protein and tungsten molecules. The level of tungsten required from the various sources was different, but in all cases it was at least an order of magnitude greater than the typical soluble tungsten levels measured in commercial PFS. 2009 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19645002     DOI: 10.1002/jps.21778

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  14 in total

1.  Chemical modifications in therapeutic protein aggregates generated under different stress conditions.

Authors:  Quanzhou Luo; Marisa K Joubert; Riki Stevenson; Randal R Ketchem; Linda O Narhi; Jette Wypych
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 2.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

3.  Classification and characterization of therapeutic antibody aggregates.

Authors:  Marisa K Joubert; Quanzhou Luo; Yasser Nashed-Samuel; Jette Wypych; Linda O Narhi
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

4.  Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products.

Authors:  Andrea Allmendinger
Journal:  Pharm Res       Date:  2021-04-26       Impact factor: 4.200

5.  Interchangeability, immunogenicity and biosimilars.

Authors:  Hans C Ebbers; Stacy A Crow; Arnold G Vulto; Huub Schellekens
Journal:  Nat Biotechnol       Date:  2012-12       Impact factor: 54.908

6.  T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia.

Authors:  Tina Rubic-Schneider; Masataka Kuwana; Brigitte Christen; Manuela Aßenmacher; Otmar Hainzl; Frank Zimmermann; Robert Fischer; Vera Koppenburg; Salah-Dine Chibout; Timothy M Wright; Andreas Seidl; Michael Kammüller
Journal:  Blood Adv       Date:  2017-02-09

7.  Development of biotechnology products in pre-filled syringes: technical considerations and approaches.

Authors:  Advait Badkar; Amanda Wolf; Leigh Bohack; Parag Kolhe
Journal:  AAPS PharmSciTech       Date:  2011-05-04       Impact factor: 3.246

Review 8.  Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates.

Authors:  Paul Chamberlain; Bonita Rup
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

9.  Precipitation of a monoclonal antibody by soluble tungsten.

Authors:  Jared S Bee; Stephanie A Nelson; Erwin Freund; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

Review 10.  Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.

Authors:  Anna N Ilinskaya; Marina A Dobrovolskaia
Journal:  Toxicol Appl Pharmacol       Date:  2016-01-07       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.